psalexa
logo

Hypertrophic Scars Therapeutics Pipeline Analysis, 2017

Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11348
Available Format:
Pages: 47

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Hypertrophic scars occur due to the deposition of excessive amounts of collagen during the healing process of cuts, burns, and body piercings. Hypertrophic scars become raised, swollen and reddened during wound healing causing them to stand out from the surrounding skin. These scars can itch and be painful, and are uniform. Hypertrophic scar may contain nerves and blood vessels and these scars are often found on the breastbone, ears, and shoulders. Positive Pre-clinical and clinical trial results of the drugs being developed for the treatment of hypertrophic scars, and funding from the healthcare organizations are the factors, driving the growth of the hypertrophic scars pipeline. RXi Pharmaceuticals Corporation is in the process of developing RXI-109 as a connective tissue growth factor inhibitor for the treatment of hypertrophic scars.

 

HYPERTROPHIC SCARS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

Hypertrophic Scars Therapeutics

Pipeline Analysis

As of November 2017, hypertrophic scars therapeutics pipeline comprises of nine drug candidates in different stages of development. 

Competitive Landscape

Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry